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Professor Patrick Francioli and myself were honoured 
to chair the International Forum on Severe Infections 
in the ICU. A programme was assembled to enable 
experts from many European countries, America, Asia 
and Africa to provide an update on key topics in the 
field of infectious diseases. The International Forum 
was comprised of state-of-the art plenary lectures and 
discussion sessions. 
This supplement, reports the proceedings of this 
International Forum and examines new developments 
in the therapy of severe infections in the ICU, in 
particular, the role of the fourth-generation cephalo- 
sporins. Two presentations covered the current resist- 
ance problems associated with Gram-positive and 
Gram-negative nosocomial pathogens, including one 
presentation devoted to Enterobacteriaceae producing 
AmpC P-lactamase. Another presentation addressed 
the changing epidemiology of severe infections in the 
ICU, and highlighted the increase in the incidence of 
Gram-positive organisms. The therapeutic implications 
associated with penicillin-resistant pneumococci and 
viridans group streptococci were also discussed. Other 
topics included the epidemiology and empiric treat- 
ment of serious infections, such as ventilator-associated 
pneumonia and severe neutropenia. 
The fourth-generation cephalosporins represent a 
unique class of cephems and are active against many 
Gram-positive and Gram-negative bacteria encoun- 
tered in serious infections, including strains resistant to 
the third-generation cephalosporins. Clinical findings 
suggest that these agents will have an important role in 
the treatment of severe community- and hospital- 
acquired infections. These issues are comprehensively 
reviewed. 
This supplement to Clinical Microbiology and Infection 
will provide readers with a wealth of up-to-date 
research and knowledge, as well as coverage of the 
lively, and sometimes controversial, discussions that 
took place at the International Forum. 
We wish to thank Dr Ian Harding (Thackerlay’s 
Ltd) for his help in the production of this supplement. 
